Oncology Central

The aptamer–siRNA conjugates: reprogramming T cells for cancer therapy


Harnessing the body’s own immune system has the potential to generate diverse, yet highly specific antitumor responses with protective long-term effects. Recent clinical advances demonstrated that new cancer immunotherapies can achieve impressive therapeutic effects, even in patients with advanced tumors of various types [1].

To view restricted content, please:



News Headlines

Comments are closed.

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.